Anti-FGFR4 antibodies and methods of use
The invention provides anti-FGFR4 antibodies and methods of using the same.
1. An isolated antibody that binds to human FGFR4, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6.
2. The antibody of claim 1 , further comprising a light chain variable domain framework sequence of SEQ ID NO: 9, 10, 11 and/or 12.
3. The antibody of claim 2 , further comprising a heavy chain variable domain framework sequence of SEQ ID NO: 13, 14, 15 and/or 16.
4. An isolated antibody that binds to human FGFR4 comprising a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8.
5. The antibody of claim 1 or 4 , which is a full length IgG1 antibody.
6. A pharmaceutical formulation comprising the antibody of claim 1 or 4 and a pharmaceutically acceptable carrier.
7. A pharmaceutical formulation comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
8. A pharmaceutical formulation comprising the antibody of claim 4 and a pharmaceutically acceptable carrier.